Correlation Between Vertex Pharmaceuticals and Dyadic International

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vertex Pharmaceuticals and Dyadic International at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vertex Pharmaceuticals and Dyadic International into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vertex Pharmaceuticals and Dyadic International, you can compare the effects of market volatilities on Vertex Pharmaceuticals and Dyadic International and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vertex Pharmaceuticals with a short position of Dyadic International. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vertex Pharmaceuticals and Dyadic International.

Diversification Opportunities for Vertex Pharmaceuticals and Dyadic International

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Vertex and Dyadic is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Vertex Pharmaceuticals and Dyadic International in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dyadic International and Vertex Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vertex Pharmaceuticals are associated (or correlated) with Dyadic International. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dyadic International has no effect on the direction of Vertex Pharmaceuticals i.e., Vertex Pharmaceuticals and Dyadic International go up and down completely randomly.

Pair Corralation between Vertex Pharmaceuticals and Dyadic International

Given the investment horizon of 90 days Vertex Pharmaceuticals is expected to generate 1.43 times less return on investment than Dyadic International. But when comparing it to its historical volatility, Vertex Pharmaceuticals is 3.18 times less risky than Dyadic International. It trades about 0.07 of its potential returns per unit of risk. Dyadic International is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  128.00  in Dyadic International on September 12, 2024 and sell it today you would earn a total of  31.00  from holding Dyadic International or generate 24.22% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Vertex Pharmaceuticals  vs.  Dyadic International

 Performance 
       Timeline  
Vertex Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Dyadic International 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Dyadic International are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite fairly conflicting basic indicators, Dyadic International demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Vertex Pharmaceuticals and Dyadic International Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vertex Pharmaceuticals and Dyadic International

The main advantage of trading using opposite Vertex Pharmaceuticals and Dyadic International positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vertex Pharmaceuticals position performs unexpectedly, Dyadic International can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyadic International will offset losses from the drop in Dyadic International's long position.
The idea behind Vertex Pharmaceuticals and Dyadic International pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance